How is this CAR a money maker? I understand that this procedure is only done once -- one time per patient in their lifetime. So hows the company gonna make money from one use?
Only for ages 3-25 roughly 600 patients.
The key is it was supported 10-0.
I would look at smaller players like TROV or BIOC for short term plays moving forward.
This is a long term play. End of year PT $102
anyone knows what happened? why stock price's ↓?
Any idea when the FDA panel decision is expected?
sell panic sell panic sell
First CAR T approved and approved 10-0!! And stock down???
Approval on CAR-T tomorrow will benefit the small caps positioned in this space such as $BLCM and $BLUE the most imo. $BLCM safety switch is already in demand let alone a cosmetic float of 25MM and almost 65% institutional ownership growing Q over Q. Take a closer look if you have not done so already. This site turned me on to Bellicum Pharma recently fwiw...
WOW !!! Lots of positive things happening at Novartis .Will be in $90,s really soon.
Yahoo Finance Insights
NVS reached a new 52 Week High at 85.08
Charles A. Henriques @ Linkedin.com
NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
San Francisco Bay Area 500 + 500 + 776 linkedin.com connections Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany
NeurogesX Inc. Next Generation -> NGX-1998 Pain ( Needs FDA Approval ) Therapy is the future, projected Global sales 5 to 6 Billion
Who says NVS isn't poised for potentially massive upward movement? How can it with performance % (quarter|performance % (q)|performance (quarter)} sitting at 9.28%? Im not sure about you guys but awesomesto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Net income down 17%!. Has management reported anything positive in the last 2 years? How do they keep their jobs?!!
Posted in $ICPT conversation
Another smart tie not involving our company when will MANAGMENT WAKE UP!!! and make moves to get analysts, investors etc... on board? Another earnings season on us (no clear date yet) and nothing will come of it. Hate to be down company but the only headline you ever see is management selling shares. A Dry Run For Novartis And Allergan's Liver Disease Assets $NVS http://www.seekingalpha.com/article/4063119
A Dry Run For Novartis And Allergan's Liver Disease Assets
Combination treatment is emerging as the latest focus in the Nash craze, and today's clinical trial tie-up between Novartis (NYSE:NVS) and Allergan (NYSE:AGN) l